Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione
- Address
- lock Available on a paid plan
Nephrology and Kidney Disease Research
At Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione, much of the clinical trial activity focuses on kidney disease and related metabolic and immune system conditions. Studies are exploring new ways to slow disease progression, reduce protein loss in the urine, and preserve kidney function in patients with chronic and inherited renal disorders.
- Focal segmental glomerulosclerosis and IgA nephropathy
- Non-diabetic chronic kidney disease and broader renal decline
- Testing treatments aimed at improving proteinuria and long-term kidney outcomes
This research is especially relevant for patients living with progressive kidney conditions, with trials designed to evaluate whether new therapies can better protect renal function and improve day-to-day disease control.
Oncology and Cancer Treatment Studies
The site also supports clinical research in neoplasms, with trials involving breast cancer, thyroid cancers, and urothelial cancer. These studies are examining whether newer cancer therapies can improve survival, strengthen the effect of standard treatment, and support better outcomes for people with advanced or high-risk disease.
- Breast cancer in the adjuvant setting
- Thyroid cancer and treatment before surgery
- Unresectable locally advanced or metastatic urothelial cancer
These trials reflect a strong interest in testing new cancer therapies, including approaches that may improve disease-free survival, extend overall survival, and refine treatment for patients with limited options.
Cardiovascular and Metabolic Research
Clinical trials at this Italian research site include work in cardiovascular diseases and nutritional and metabolic diseases. The research is aimed at understanding whether new therapies can reduce major heart-related events and better manage risk in people with chronic cardiometabolic conditions.
- Cardiovascular disease prevention and risk reduction
- Testing treatment effectiveness in people with heart and blood vessel disease
- Evaluating therapies for long-term metabolic and cardiovascular protection
This area of research is centered on improving protection against serious complications, with a focus on treatment benefit in routine clinical care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 18 therapeutic areas and 15 of 137 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 126 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
- 1AstraZeneca AB4active
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione
lock Showing 1 of 86 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety and Tolerability of ADX-038 in Participants With Complement-Mediated Kidney Disease | Adarx Pharmaceuticals Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 137 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 7 | Unknown | 2019-02-01 | 2025-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.